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Growth inhibition and differentiation induction in human
monoblastic leukaemia cells by I x-hydroxyvitamin D
derivatives and their enhancement by combination with
hydroxyurea
M Makishima, J Okabe-Kado and Y Honma
Department of Chemotherapy, Saitama Cancer Center Research Institute, 818 Komuro, Ina-machi, Kita-adachi, Saitama 362, Japan
Summary The active form of vitamin D, 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3), is a potent inducer of differentiation in myeloid leukaemia
cells, but its clinical use is limited because of its hypercalcaemic activity. We examined the ability of 1,25(OH)2D3 in combination with several
anti-cancer drugs to inhibit the proliferation of, and induce differentiation in, human monoblastic leukaemia U937 cells. Hydroxyurea (HU),
cytarabine and camptothecin showed effective synergism with 1,25(OH)2D3 with regard to growth inhibition, while daunorubicin and etoposide
had only modest synergistic effects. HU and cytarabine effectively enhanced nitroblue tetrazolium-reducing activity induced by 1,25(OH)2D3.
HU also enhanced the morphological maturation and expression of CD11b and CD14 in cells treated with 1,25(OH)2D3. Among the anti-
cancer drugs examined, HU had the greatest synergistic effects with 1,25(OH)2D3 with regard to growth inhibition and differentiation induction
in U937 cells. HU also enhanced the differentiation of other myeloid leukaemia HL-60, ML-1, THP-1, P39/TSU, P31/FUJ and NB4 cells
induced by 1,25(OH)2D3 and that of U937 cells induced by 24-epil,25(OH)2D2 and 1,25(OH)2D7. Interestingly, 1OC(OH)D derivatives (lax-
hydroxyvitamin D3, D2, D4 and D7) effectively induced the differentiation of monoblastic leukaemia U937, P39/TSU and P31/FUJ cells. HU also
enhanced the growth inhibition and differentiation of U937 cells induced by 1a(OH)D derivatives. As 1 cc(OH)D derivatives preferentially act on
monocytic cells, they may be useful in the treatment of acute monocytic leukaemia, both alone and in combination with HU.
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The prognosis of acute myeloid leukaemia has recently improved
through the application of intensive chemotherapy and bone
marrow transplantation. However, intensive chemotherapy is not
used in elderly patients or in patients with hypoplastic leukaemia
or myelodysplastic syndrome because of severe complications.
The incidence of induction death among elderly patients in their
initial induction therapy, even when supported with cytokines, is
higher than 10% (Schiffer, 1996). Indications for bone marrow
transplantation are limited to young patients with HLA-matched
donors (Goldman, 1994). Differentiation therapy is one possible
approach for surviving patients who cannot be treated with
intensive chemotherapy or bone marrow transplantation.
Differentiation therapy has been used successfully to treat acute
promyelocytic leukaemia (Degos et al, 1995). All-trans retinoic
acid induces complete remission in more than 90% of patients
with acute promyelocytic leukaemia with a t (15;17) chromosomal
translocation. However, the use ofall-trans retinoic acid is limited
to acute promyelocytic leukaemia. Vitamin D is another potential
inducer for differentiation therapy. The active form of vitamin D,
la,25-dihydroxyvitamin D3 (1,25(OH)2D3), induces differentia-
tion in mouse and in human leukaemia cells (Abe et al, 1981;
Miyaura et al, 1981) and prolongs the survival of mice inoculated
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with myeloid leukaemia cells (Honma et al, 1983). However,
clinical trials of 1,25(OH)2D3 in patients with myelodysplastic
syndrome have not been successful because of hypercalcaemia
(Koeffler et al, 1985). Several analogues of 1,25(OH)2D3 that
show anti-cancer activity and only weak activity for inducing
hypercalcaemia have been developed, but they are not yet avail-
able for the clinical treatment of cancer or leukaemia (Abe et al,
1991; Pakkala et al, 1995). To overcome the adverse effects of
vitamin D, we are investigating the effects of the combination of
1,25(OH)2D3 with other drugs (Makishima and Honma, 1996;
Makishima et al, 1996). As the combination of all-trans retinoic
acid with low doses of anti-cancer drugs produced better results
than either drug alone for the treatment of acute myeloid
leukaemia (Venditti et al, 1995), in this study, we investigated the
effects of the combination of 1,25(OH)2D3 and its analogues with
various anti-cancer drugs on growth inhibition and differentiation
induction in myelomonocytic leukaemia cells.
MATERIALS AND METHODS
Materials
la,25-Dihydroxyvitamin D7 (1,25(OH)2D7), 24-epi-lac,25-dihy-
droxyvitamin D2 (24-epi-1,25(OH)2D2), 1a-hydroxyvitamin D3
(1a(OH)D3), 1a(OH)D2, 1a(OH)D4 and la(OH)D7 were synthe-
sized (Figure 1) (Tachibana and Tsuji, 1992) and donated by the
Fine Chemical Research Center, Nisshin Flour Milling (Saitama,
Japan). Chlorambucil, daunorubicin, actinomycin D, hydroxyurea
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Figure 1 Chemical structures of vitamin D derivatives
(HU), cytarabine (Ara-C) and camptothecin were purchased from
Sigma (St Louis, MO, USA), and 1,25(OH)2D3 was from Wako
Pure Chemical Industry (Osaka, Japan). Etoposide was obtained
from Nippon Kayaku (Tokyo, Japan).
Cell lines and cell culture
Human myeloid leukaemia U937, HL-60, ML-1, THP-1, P39/TSU,
P31/FUJ and NB4 cells (Lanotte et al, 1991) were cultured in
suspension in RPMI 1640 medium containing 10% fetal bovine
serum and 80 gg ml gentamicin at 37°C in a humidified atmos-
phere of5% carbon dioxide in air (Makishima et al, 1996).
Cell growth and differentiation
Suspensions of cells were cultured with or without the test
compounds in multidishes. The cells were counted in a Model ZM
Coulter Counter (Coulter Electronics, Luton, UK). Nitroblue tetra-
zolium (NBT) reduction was assayed colorimetrically (Makishima
et al, 1996). Lysozyme activity in the conditioned medium was
determined using a lysoplate (Makishima et al, 1996). One unit is
equivalent to 1 ,ug ml-1 egg-white lysozyme. Cell morphology was
examined in cell smears stained with May-Gruinwald and Giemsa
solutions (Merck, Darmstadt, Germany).
Analysis of the effects of combinations of drugs
The interaction of the two compounds was quantified by deter-
mining the combination index (CI) according to the classic
isobologram equation:
CI = D1/Dx1 + D2/Dx2
where Dx is the concentration of one drug alone required to
produce an effect andDi and D2 are the doses ofcompounds l and
2, respectively, in combination that produce the same effect
(Berenbaum, 1989). Using this analysis, the combined effects of
the two drugs can be assessed as being either additive (CI = 1),
synergistic (CI < 1) or antagonistic (CI > 1). An isobologram was
also used to determine the effect of combinations of drugs
(Berenbaum, 1989). Concentration-dependent effects were deter-
mined from isoeffective concentrations foreach compound and for
one compound with fixed concentrations of another. The additive
lines were indicated as calculated by mode I and mode II systems
(Steel and Peckham, 1979).
Flow cytometry
Expression of the granulocyte- and monocyte-specific antigens
CDllb and CD14 on the cell surface was determined using in-
direct immunofluorescent staining and flow cytometry
(Makishima and Honma, 1996). Mouse monoclonal antibodies to
CDl1b (2LPM19c), CD14 (TUK4), control mouse IgGI, IgG2a
and FITC-conjugated F(ab )2 fragment ofgoat antimouse IgG were
obtained from Dako (Glostrup, Denmark). The stained cells were
assayed using a flow cytometer (Epics XL; Coulter Electronics)
Table 1 Effects of the combination of anticancer drugs and 1,25(OH)2D3 on growth inhibition and NBT-reducing activity of human monoblastic leukaemia U937
cells
Drugs IC50 for Clb NBT reductionc Ratiod
growth suppression (A56( per 107 cells)
-VD3 +VD3a -VD3 +VD3
Chlorambucil 5.19gM 3.90 gm 0.90 1.15 ± 0.13 2.14+ 0.27 1.9
Daunorubicin 2.73 nM 1.53 nM 0.71 0.93 ± 0.07 2.17+ 0.14 2.3
Actinomycin D 88.1 pM 76.7 pM 1.02 0.65 ± 0.07 2.06 ± 0.06 3.2
HU 50.7gM 15.8gM 0.46 1.26 ± 0.25 7.78 ± 0.34e 6.2
Ara-C 6.86nM 2.41 nM 0.50 1.02 ±0.14 3.56 0.46 3.5
Camptothecin 9.84 nM 4.14 nM 0.57 1.84 ± 0.16 3.70 0.38 2.0
Etoposide 38.3 nM 25.3 nM 0.81 1.20 ± 0.03 2.82 0.10 2.4
None 0.54 ± 0.04 1.42 0.09 2.6
Cells (5 x 104 cells ml-') were treated with anti-cancer drugs in the absence or presence of 1,25(OH)2D3 (VD3) for 4 days. IC50 values were determined from the
means of triplicate data and values of NBT reduction represent the means ± SD of three separate experiments. alC50 values for anti-cancer drugs in the
presence of 3 x 10-9 M 1,25(OH)2D3. bCombination index (Cl) at IC50 for growth inhibition. Cl values at a fixed concentration of 1,25(OH)2D3 (3 x 10-9 M) were
calculated as described in the Materials and methods. IC 5 of 1,25(OH)2D3 was 2.01 x 10-8 M. In this assay, Cl = 1 indicates an additive effect, Cl <1 indicates
synergism and Cl >1 indicates antagonism. cNBT reduction in the cells treated with anti-cancer drugs at their IC50 for growth inhibition in the absence or
presence of 3 x 1 -9 M 1,25(OH)2D3. 1,25(OH)2D3 at the IC 50 induced the activity to 4.64 A560. dRatio of the NBT reduction: +1,25(OH)2D3 /-1,25(OH)2D3.
ep<0.0005 compared with other anti-cancer drugs plus 1,25(OH)2D3.
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Figure 2 Effects of the combination of HU and 1,25(OH)2D3 with regard to growth inhibition and differentiation induction in human monoblastic leukaemia
U937 cells. (A) Isobologram for 1,25(OH)2D3 and HU at the IC50 for growth inhibition. The dashed lines and 11 indicate additive interaction calculated by mode
and 11 systems respectively (Steel and Peckham, 1979). In mode 11, when the dose of HU is chosen, an isoeffect curve is calculated by taking the dose
increment of 1,25(OH)2D3 that gives the required contribution to IC.,, estimating how much HU reduces the requirement of 1,25(OH)2D3. (B) NBT-reducing
activities of cells treated with a combination of HU and 0 (0), 3 x 10-'0 M (@), 3 x 10-9 M (A) or 3 x 10 8 M (U) 1,25(OH)2D3. (C) CD1lb expression by cells treated
with a combination of HU and 0 (0), 3 x 0-10 M (A) or 3 x 10-9 M (U) 1,25(OH)2D3. 1,25(OH)2D3 at 3 x 1 6 M induced the expression to 6.41 units. Cells
(5 x 104 cells ml-') were cultured with test compounds for 4 days. Values represent the means ( ± SD) of three separate experiments
and the mean fluorescence intensity of fluorescence-positive cells
was calculated using the Immuno-4 histogram analysis program
(Coulter), with mouse immunoglobulin of the same isotype as a
negative control. The Immuno-4 program subtracts a control
histogram from a test histogram to calculate the mean fluorescence
intensity in the test histogram (Overton, 1988).
Statistical evaluation
Statistical analyses were performed using an unpaired two-tailed
Student's t-test.
RESULTS
Effects of the combination of anti-cancer drugs with
1 ,25(OH)2D3 on the growth and differentiation of human
monoblastic leukaemia U937 cells
We examined several anti-cancer drugs in combination with
1,25(OH)2D3 to determine the effects on growth inhibition in human
monoblastic leukaemia U937 cells. Chlorambucil is an alkylating
agent; daunorubicin andactinomycin D are antibiotics; HU and Ara-
C are inhibitors of nucleotide metabolism; and camptothecin and
etoposide are inhibitors oftopoisomerases. These drugs all inhibited
the proliferation ofU937 cells concentration dependently; their IC50
values are indicated in Table 1. The effects of the combination of
anti-cancer drugs and 1,25(OH)2D3 were determined using the CI
calculated from the IC50 values of anti-cancer drugs in the presence
of 3 x 10-9 M 1,25(OH)2D3. HU inhibited the proliferation of U937
cells at an IC50 of 50.7 gM in the absence of 1,25(OH)2D3 and at an
IC5' of 15.8 gM in its presence (CI = 0.46, indicating synergism).
The confidence intervals (CIs) for Ara-C, camptothecin, daunoru-
bicin andetoposide were0.50, 0.57, 0.71 and0.81, respectively, also
indicating synergism. The combinations ofchlorambucil and actino-
mycin D with 1,25(OH)2D3 were additive.
We examined the effects of anti-cancer drugs in combination
with 1,25(OH)2D3 on NBT-reducing activity, a typical marker of
myelomonocytic differentiation, in U937 cells. The anti-cancer
drugs showed only weak activity for inducing NBT reduction
(Table 1). Next, the NBT-reducing activity induced by anti-cancer
drugs in combination with 3 x 10-9 M 1,25(OH)2D3 was examined.
HU plus 1,25(OH)2D3 effectively increased the activity 6.2-fold
from HU alone and 5.5-fold from 1,25(OH)2D3 alone (Table 1).
Camptothecin and Ara-C in combination with 1,25(OH)2D3
modestly induced this activity. Among the anti-cancer drugs
we examined, HU had the greatest synergistic effect with
1,25(OH)2D3 for growth inhibition and induction ofNBT-reducing
activity in U937 cells.
Effects of HU plus 1,25(OH)2D3 on growth inhibition and
differentiation induction in human myelomonocytic
leukaemia cells
The concentration-dependent effects of the combination of HU
with 1,25(OH)2D3 on U937 cells were examined. Isoboles for
growth inhibition show that their combination is synergistic and
the presence of HU markedly reduced effective concentrations of
1,25(OH)2D3 (Figure 2A). HU up to 75 gM induced NBT-reducing
activity of U937 cells only slightly (Figure 2B). While
1,25(OH)2D3 at 3 x 10-10 M did not induce NBT-reducing activity
of U937 cells, in the presence of75 gM HU, it effectively induced
this activity to 5.96 A560' which is similar to the value (5.90 A560)
with a 100-fold greater concentration (3 x 1-8 M) of 1,25(OH)2D3
(Figure 2B). Morphologically, monoblastic U937 cells were
induced to differentiate into monocytic cells by 1,25(OH)2D3 and
became more mature, having abundant and grey cytoplasm and a
chromatin-condensed nucleus with the addition of HU (data not
shown). HU also effectively enhanced the expression ofCD1lb in
U937 cells induced by low concentrations of 1,25(OH)2D3 (Figure
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Figure 3 Effects of the combination of HU and 1,25(OH)2D3 with regard to the NBT-reducing activity of human myeloid leukaemia HL-60 (A), ML-1 (B), THP-1
(C), P39/TSU (D), P31/FUJ (E) and NB4 cells (F). Cells (5 x 104 cells ml-') were cultured with HU in combination with 0 (0), 3 x 10-9 M (A) or 3 x 10-8 M (U)
1 ,25(OH)2D3 for 4 days. Values represent the means ± SD of three separate experiments
2C). HU at 75 gM plus 1,25(OH)2D3 at 3 x 10-9 M increased this
intensity to 8.00 units, which is greater than 6.41 units with 3 x
106 M 1,25(OH)2D3 alone. The enhancing effect of HU on CD14
expression induced by 1,25(OH)2D3 in U937 cells was weak (data
not shown). Thus, HU effectively enhanced several differentiation
markers in U937 cells treated with 1,25(OH)2D3.
Next, we examined the combination ofHU and 1,25(OH)2D3 on
the differentiation of other myelomonocytic leukaemia cells. HU
did not induce NBT-reducing activity in promyelocytic HL-60 and
myeloblastic ML-1 cells, but enhanced the activity induced by
1,25(OH)2D3 (Figure 3A and B). HU alone induced NBT-reducing
activity in monoblastic THP-1 cells but not in other monoblastic
P39/TSU or P31/FUJ cells. It also effectively enhanced the differ-
entiation of these cells induced by 1,25(OH)2D3 (Figure 3C-E).
NB4 cells are promyelocytic leukaemia cells with a t(15;17) chro-
mosomal translocation and have been reported to be resistant to
1,25(OH)2D3 (Testa et al, 1994). HU also induced the NBT-
reducing activity in NB4 cells in combination with 1,25(OH)2D3
(Figure 3F). Thus, HU plus 1,25(OH)2D3 effectively induces the
differentiation ofmyelomonocytic leukaemia cells.
Effects of HU in combination with vitamin D derivatives
on growth inhibition and differentiation induction in
U937 cells
24-Epi-1,25(OH)2D2 and 1,25(OH)2D7 have been reported to
exhibit less hypercalcaemic activity than 1,25(OH)2D3 and to be
able to induce the differentiation ofHL-60 cells (Sato et al, 1991).
They also induced the NBT-reducing activity of U937 cells, and
HU effectively enhanced the activities induced by their suboptimal
concentrations (Figure 4A). 24-Epi-1,25(OH)2D2 and 1,25-
(OH)2D7 inhibited the proliferation of U937 cells concentration
dependently, with IC50 values of 2.25 x 10-7 M and 2.28 x 10-7 M
respectively (data not shown). At a low concentration of
9 x 10-9 M, they slightly inhibited the proliferation of U937 cells
and augmented the growth inhibition in combination with 50 gM
HU (Table 2).
We have previously reported that Ia(OH)D3 induces the differen-
tiation ofmonoblastic leukaemia cells as well as 1,25(OH)2D3 and is
less toxic than 1,25(OH)2D3 (Honma et al, 1983; Okabe-Kado et al,
1992). We examined the effects of several lac(OH)D derivatives on
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Table 2 Growth inhibition in human monoblastic leukaemia U937 cells by
vitamin D derivatives in combination with HU
Compounds Growth (% of control)
- HU + HU Ratioa
None 100 54+3 100
1,25(OH)2D3 (3 x 10-9M) 74± 1 25 ± 3 46
24-Epi1,25(OH)2D2 (9 x 10-9 M) 87 + 2 33 ± 1 61
1,25(OH)2D7 (9x 10-9 M) 89 ±2 32± 1 59
1a(OH)D3 (3 x 10-8M) 72 ± 2 27± 1 50
1a(OH)D2 (6 x 10-8M) 91 ± 2 31 ± 1 57
1a(OH)D4 (6 x 10-8M) 89± 1 28 ±3 52
1a(OH)D7 (6 x 10-8M) 100 ±4 27 ±2 50
Cells (5 x 104 cells ml-') were cultured with vitamin D derivatives in the
absence or presence of 50gM HU for 4 days. 9Ratio (%) represents the
growth of cells in combination with HU compared with that of cells treated
with 50gM HU alone.
growth inhibition and differentiation induction in U937 cells in
combination with HU. la(OH)D3 inhibited proliferation with anIC50
value of 0.67 x 10-7 M and induced myelomonocytic differentiation
markers, such as the NBT-reducing and lysozyme activities ofU937
cells (Figure 4B, data not shown). HU effectively enhanced the
NBT-reducing activity in U937 cells induced by la(OH)D3 (Figure
4B). For example, 1.2 x 10-8 M la(OH)D3 plus 50gM HU induced
this activity to 9.02A560' while this activity was 8.54A560 with 1.2 x
1o-6 M la(OH)D3 alone, indicating that lIt(OH)D3 was more than
100 times as active in the presence of HU. la(OH)D3 at 3 x 10-8 M
slightly inhibited the proliferation ofU937 cells, but augmented the
inhibition in combination with HU (Table 2). la(OH)D2, 1 x(OH)D4
A *.
and la(OH)D7 also inhibited the proliferation with IC50 values of
1.35 x 10-7, 1.47 x 10-7 and 3.25 x 10-7 M, respectively (data not
shown), and induced the differentiation ofmonoblastic U937 (Figure
4C), P39/TSU and P3l/FUJ cells, but not of promyelocytic HL-60
cells (data not shown). Among these four la(OH)D derivatives,
la(OH)D3 was the most effective in inhibiting the proliferation.of
U937 cells (P<0.005, compared at IC50). At the IC50 values for
growthinhibition, lc(OH)D3, la(OH)D2, la(OH)D4 and Ia(OH)D7
induced NBT-reducing activity ofU937 cells from 0.83A560 to 5.80,
5.50, 6.08 and 5.84 A560' respectively, and lysozyme activity from
1.99 units to 5.03, 5.11, 6.34 and 6.03 units, respectively (data not
shown), indicating that la(OH)D4 was slightly more effective for
inducing these activities than the others. The NBT-reducing activity
induced by these la(OH)D derivatives in U937 cells was also
effectively enhancedby HU (Figure4C). HU enhanced the induction
of NBT reduction by la(OH)D4 slightly more effectively than
that by la(OH)D2 and l1z(OH)D7. At a concentration of6 x 10-8 M,
la(OH)D2 and la(OH)D4 inhibited the proliferation of U937
cells only slightly, while lIc(OH)D7 had no such effect, but they
augmented the growth-inhibitory activity with HU (Table 2).
Thus, the combination ofHU with la(OH)D derivatives is effective
for inhibiting the proliferation and inducing the differentiation
ofU937 cells.
DISCUSSION
Among the anti-cancer drugs we examined, HU showed the
greatest synergistic effect with 1,25(OH)2D3 with regard to growth
inhibition and differentiation induction in U937 cells. Ara-C and
camptothecin showed modest synergism with regard to growth
inhibition, and Ara-C enhanced the differentiation induced by
1,25(OH)2D3 second only to HU. In another study, treatment with
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Figure 4 Effects of vitamin D derivatives in combination with HU with regard to the induction of NBT-reducing activity in human monoblastic leukaemia U937
cells. (A) NBT-reducing activities of cells treated with 24-epi-1,25(OH)2D2 (0, 0) or 1,25(OH)2D7 (A, A) in the absence (0, A) or presence (0, A) of 50gM HU.
(B) NBT-reducing activities of cells treated with 1a(OH)D3 in the absence (0) or presence (0) of 50grm HU. (c) NBT-reducing activities of cells treated with
Ia(OH)D2 (0, *), la(OH)D4 (A, A) or la(OH)D7 (0, *) in the absence (0, A, El) or presence (0, A, *) of 50gM HU. Cells (5 x 104 cells ml-') were cultured
with the test compounds for 4 days. Values represent the means ± SD of three separate experiments
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1,25(OH)2D3 increased the cytotoxicity of Ara-C and HU against
HL-60 cells (Studzinski et al, 1986). HU inhibits nucleotide
metabolism by inhibiting ribonucleotide reductase and Ara-C also
inhibits nucleotide synthesis (Calabresi and Chabner, 1996). HU
enhances the differentiation of HL-60 cells induced by all-trans
retinoic acid (Yen et al, 1987). Ara-C induces the differentiation of
some myeloid leukaemia cells and low doses of Ara-C have been
used to treat acute myeloid leukaemia (Housset et al, 1982). Other
inhibitors of nucleotide metabolism also induce the differentiation
of myeloid leukaemia cells (Bodner et al, 1981; Ishiguro and
Sartorelli, 1985). These findings indicate that some inhibitors of
nucleotide metabolism may induce leukaemia cells to differentiate
and to enhance differentiation induced by other compounds more
effectively than other types ofanti-cancer drugs.
HU is useful for treating chronic myelogenous leukaemia and,
when administered orally at daily doses from 500 to 3000 mg, for
controlling blood cell counts within desirable ranges (Athens,
1993). Its major adverse effect is bone marrow suppression, but
the bone marrow recovers promptly ifthe drug is discontinued for
a few days. Thus, HU can be used safely in elderly patients.
Pharmacokinetic studies have shown that serum concentrations of
HU after a single oral administration of 1000 mg reach 20-
30gg ml-' (263-394 gM) in 1-3 h, then gradually decrease and
remain higher than 5 ,tg ml-' (66 ltM) for at least 10 h (Davidson
and Winter, 1963; Bolton et al, 1965). These findings indicate that
the concentrations of HU needed to enhance the anti-leukaemic
activity of vitamin D derivatives can be achieved clinically.
In this study, we observed the differentiation-inducing activities
of lox(OH)D derivatives. After the administration of Ix(OH)D3, it
is converted to an active form, 1,25(OH)2D3, by liver 25-
hydroxylase (Holick et al, 1975). ho(OH)D3 was more potent than
1,25(OH),D3 in increasing the survival time of mice inoculated
with mouse myeloid leukaemia Ml cells (Honma et al, 1983). The
relatively stable concentrations of 1,25(OH),D3 after the adminis-
tration of lIc(OH)D3 compared with 1,25(OH)2D3 may contribute
to the advantage offered by lot(OH)D3. Interestingly, lIx(OH)D3
induced the differentiation of monoblastic leukaemia cells in
vitro and was converted to 1,25(OH)2D3 in the cells (Okabe-Kado
et al, 1992). As monocytes also have 24-hydroxylase activity
(Kamimura et al, 1995) and lac, 24-dihydroxyvitamin D3 can
induce the differentiation of HL-60 cells to a similar extent as
1,25(OH)2D3 (Tanaka et al, 1982), Ix(OH)D3 may act by being
converted to 1,25(OH)2D3 and Ia, 24-dihydroxyvitamin D3 in
monocytic cells. Thus, 1 x(OH)D3 affects leukaemia cells with
monocytic characteristics both directly and indirectly. Acute
monocytic leukaemia is more resistant to intensive chemotherapy
than other types of acute myeloid leukaemia and its prognosis is
poor (Fenaux et al, 1990). The use of loc(OH)D derivatives may
offer certain advantages in the treatment of monocytic leukaemia,
as (a) 1,25(OH),D3 is physiologically catabolized to an inactive
form in monocytic cells and such cells can activate Iox(OH)D and
(b) drugs can be focused against leukaemia cells of monocytic
lineage and their adverse effects against other organs can be
diminished. Other 1 x(OH)D derivatives, including 1o(OH)D2,
1 cx(OH)D4 and Ikx(OH)D7, also induced the differentiation of
myelomonocytic leukaemia cells. lox(OH)D, is 5-15 times less
toxic than lot(OH)D3 in rats (Sjoden et al, 1985). A clinical study
in post-menopausal osteopenic patients showed that loc(OH)D2 at
daily doses of less than 5.0,ug did not induce hypercalcaemia,
whereas Ixc(OH)D3 at daily doses above 1.0 gg had toxic
effects (Gallagher et al, 1994). An active form of lc-(OR)D7,
1,25(OH)2D7, has less hypercalcaemic activity (Sato et al, 1991).
Therefore, the 1 x(OH)D derivatives may be useful for treating
monocytic leukaemia. Pharmacokinetics for serum concentrations
of 1cx(OH)D derivatives and their metabolites after administration
should be further investigated. HU also effectively enhanced the
differentiation induced by the Iax(OH)D derivatives. The combina-
tion of la(OH)D derivatives with HU may be a promising candi-
date for 'chemo-differentiation therapy' of acute monocytic
leukaemia.
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